Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 2Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 69Carcinoma, Non-Small-Cell Lung 62Stomach Neoplasms 32Prostatic Neoplasms 21Nasopharyngeal Carcinoma 20Lung Neoplasms 20Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Neoplasm Metastasis 8Head and Neck Neoplasms 7Inflammatory Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5HER2-positive Breast Cancer 5Adenocarcinoma 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4NSCLC 4Carcinoma, Squamous Cell 4Sarcoma 3Nasopharyngeal Neoplasms 3Hypopharyngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Ovarian Epithelial 3Breast Diseases 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Squamous Cell Lung Cancer 2

Interventions

Docetaxel 2Sunitinib 1Prednisone 1PE regimen 1Injections 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Hormone Refractory Prostate Cancer × Docetaxel × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00795171 2010-08-18

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Medical University of Vienna

Phase 2 Unknown
60 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡